Cardiac safety of sofosbuvir-based direct-acting antivirals in hepatitis C patients with pre-existing heart disease. [PDF]
Hanafy AS +7 more
europepmc +1 more source
Safety and Drug-Drug Interaction Burden of Direct-Acting Antiviral Therapy for Hepatitis C: A Single-Center Community Hospital Analysis. [PDF]
Okabe S +5 more
europepmc +1 more source
Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus. [PDF]
Aras M, Yayintas OT.
europepmc +1 more source
Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study. [PDF]
Enayet A +5 more
europepmc +1 more source
Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial. [PDF]
Muhamad NA +8 more
europepmc +1 more source
Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals. [PDF]
Bai X, Ye B, Gao S, Zhan P, Liu X.
europepmc +1 more source
Immediate Donor-Derived Hepatitis C Transmission Following Kidney Transplantation: A Two-Case Observation. [PDF]
Chen IR, Su WP, Lai PC.
europepmc +1 more source
Comparative effectiveness of antiviral therapies in chronic hepatitis B and C management. [PDF]
Tiwari A +3 more
europepmc +1 more source
Review on drug repositioning of some FDA-approved drugs for treatment of cancer/microbial diseases. [PDF]
Ismail MMF +4 more
europepmc +1 more source
Liver stiffness by non-invasive tests predicts hepatocellular carcinoma and liver-related complications following viral eradication with direct-acting antivirals in chronic hepatitis C: a retrospective cohort study. [PDF]
Ananchuensook P +3 more
europepmc +1 more source

